drugset
Drugs / Allogeneic Adoptive Immune Therapy
last change Dec 2024 re-read 3 minutes ago

Allogeneic Adoptive Immune Therapy

also known as AAIT

Cell therapy

Developed for
AIDS · HIV infectious disease · immunodeficiency disease
Investigated by
Beijing 302 Hospital · Shanghai Public Health Clinical Center · The 3th people's hospital of Shenzhen City · The 4th people's hospital of Nanning City · The 6th people's Hospital of Xinjiang province · Yunnan Provincial Infectious Disease Hospital

Trials 2

today NCT04098770 · Ph 2 NCT02651376 · Ph 1/2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT02651376 Sep 2015 → Apr 2017 HIV infectious disease, immunodeficiency disease Beijing 302 Hospital Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04098770 Oct 2019 → Dec 2023 AIDS Beijing 302 Hospital Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as allogeneic adoptive immune therapy “The purpose of this study is to investigate the safety and initial efficacy of allogeneic adoptive immune therapy (AAIT) for advanced AIDS patients.” NCT02651376 ↗
1

NCT04098770 ↗
Known as AAIT “The purpose of this study is to investigate the safety and initial efficacy of allogeneic adoptive immune therapy (AAIT) for advanced AIDS patients.” NCT02651376 ↗
1

“we developed an HLA-mismatched allogeneic adoptive immune therapy (AAIT) specifically targeting this patient population.” PMID 38935839 ↗ Jun 2024
Modality Cell therapy “Immune cell therapy in combination with anti-infection and anti-HIV therapy may open a new direction for advanced AIDS patients” NCT02651376 ↗
Route Intravenous “taken i.v.” NCT02651376 ↗